Anew Medical, Inc. WENA
Day range unavailable
52-week range unavailable
- Market cap
- 15.44M
- Shares out
- 21.26M
- Beta
- 0.02
5Y -1.7540 (-70.73%)
Key statistics
- Enterprise value
- 19.04M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -168.17K
- Total cash
- 845.34K
- Total debt
- 3.90M
- Return on equity
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 1.04
- 200-day average
- 1.28
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
About Anew Medical, Inc.
Anew Medical, Inc., a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan's Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases. Anew Medical, Inc. is based in Omaha, Nebraska.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- anewmeds.com
News
Your note
Sign in to keep a note on WENA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHARDAN MONTEREY INVESTMENTS LLC | Beneficial Owner of more than 10% of a Class of Security | Sale | Jul 1, 2024 | 1,284,360 |